| Chemical Properties | Back Directory | [Boiling point ]
469.931±45.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.145±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
10.094±0.15(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Z4P is a BBB-penatrable IRE1 inhibitor with an IC50 of 1.13 μM. Z4P in combination with Temozolomide (HY-17364) inhibits the growth and recurrence of glioblastoma and has anti-tumor activity[1]. | [in vivo]
Z4P (300 μg/kg; intraperitoneal injection; 186 days) combined with Temozolomide (HY-17364) shows antitumor activity in a mouse glioblastoma model[1]. | Animal Model: | Male NMRI-Foxn1nu/Foxn1nu mice with glioblastoma[1] | | Dosage: | 300 μg/kg | | Administration: | Intraperitoneal injection (i.p.); 186 days | | Result: | Decreased the splicing of XBP1 mRNA.
Arrested tumor growth.
Prolonged relapse-free survival.
|
| [References]
[1] Pelizzari-Raymundo D, et al. A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment. iScience. 2023 Apr 24;26(5):106687. DOI:10.1016/j.isci.2023.106687 |
|
|